Account for the added KPV component
KLOW's additional KPV component requires its own documentation; it cannot be assumed to share the evidence of a GLOW reference. FDA reports a lack of identified human exposure data for KPV drug products.
Documentation to request
Obtain all four component quantities and identity records. Confirm the ratio rather than using the trade name as a complete specification.
Regulatory context: FDA: substance-specific safety concerns. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.
Related guidance: Evidence review before expanding a clinic menu. These references support a review, not a treatment recommendation or supply authorization.